Sinzinger H, Virgolini I, Kudlacek P
Atheroskleroseforschungsgruppe (ASF) Wien.
Wien Klin Wochenschr. 1991;103(13):381-7.
The therapeutic effect of bezafibrate (1 x 400 mg/day) on plasma lipids and coronary risk was evaluated in an open, prospective multicenter study in 763 patients with isolated hypercholesterolemia or mixed hyperlipidemia. During the 16 weeks of treatment (712 patients were included in the evaluation) bezafibrate lowered total cholesterol (C) by 22%, triglycerides (TG) by 32% and LDL-C by 20% and increased HDL-C by 29.6%. The ratio of C/HDL-C decreased from 8.8 +/- 2.0 to 5.4 +/- 1.5, i.e. a reduction of 36%. A comparable hypolipemic effect of bezafibrate was seen in all the subgroups of isolated hypercholesterolemia (C -21%, LDL-C -31%, HDL-C + 28%, TG -10%) and mixed hyperlipidemia (C -22%, LDL-C -16%, HDL-C + 30%, TG -37%). During treatment the coronary risk factor estimated by the SPIRIT calculator decreased from 5.5 to 2.5 (-54.5%) in male patients (n = 499). The calculated incidence of myocardial infarction thereby decreased from 225.7 to 111.9 (-50.4%). This study shows that bezafibrate effectively improves lipid metabolism in both isolated hypercholesterolemia and mixed hyperlipidemia and results in a decreased coronary risk.
在一项针对763例单纯高胆固醇血症或混合性高脂血症患者的开放性前瞻性多中心研究中，评估了苯扎贝特（每日1次，每次400毫克）对血脂和冠心病风险的治疗效果。在为期16周的治疗期间（712例患者纳入评估），苯扎贝特使总胆固醇（C）降低了22%，甘油三酯（TG）降低了32%，低密度脂蛋白胆固醇（LDL-C）降低了20%，高密度脂蛋白胆固醇（HDL-C）升高了29.6%。C/HDL-C比值从8.8±2.0降至5.4±1.5，即降低了36%。在单纯高胆固醇血症的所有亚组（C降低21%，LDL-C降低31%，HDL-C升高28%，TG降低10%）和混合性高脂血症（C降低22%，LDL-C降低16%，HDL-C升高30%，TG降低37%）中，均观察到苯扎贝特具有类似的降血脂作用。在治疗期间，男性患者（n = 499）通过SPIRIT计算器估算的冠心病风险因素从5.5降至2.5（-54.5%）。由此计算出的心肌梗死发病率从225.7降至111.9（-50.4%）。这项研究表明，苯扎贝特可有效改善单纯高胆固醇血症和混合性高脂血症患者的脂质代谢，并降低冠心病风险。
